At least one dose level of AMG 176 will achieve acceptable safety and tolerability in
participants with relapsed or refractory multiple myeloma and participants with relapsed or
refractory acute myeloid leukemia
This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and
dose-exploration study of AMG 176 administered IV in participants with relapsed or refractory
multiple myeloma and participants with relapsed or refractory acute myeloid leukemia The
study will be conducted in five parts.
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.